Swiss-listed BB Biotech celebrates 30 years of outperformance with fund manager Dr Daniel Koller confident the biotechnology slump of the past two years will in time look like a small setback.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
